Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab for Wearing Off Phenomena in MS Patients on Ocrelizumab
NCT07389590Phase 4Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4 trial of ublituximab in multiple sclerosis (MS) (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Proportion of Patients with Wearing-Off at 11 months. Started Feb 2026; status: recruiting.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07389590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389590.